Cyclin-dependent kinase 4/6 inhibitors for the treatment of breast cancer: a review of preclinical and clinical data
N Vidula, HS Rugo - Clinical breast cancer, 2016 - Elsevier
For millions of women, breast cancer remains a potentially life-endangering diagnosis. With
advances in research, new therapies targeted to tumor biology are emerging to treat the
most common form of this disease. Cyclin-dependent kinase (CDK) 4/6 inhibitors are a new
class of therapeutic agents that have the potential to improve the outcomes of patients with
hormone receptor-positive (HR+) breast cancer. Three CDK 4/6 inhibitors have been
investigated for the treatment of HR+ breast cancer, including palbociclib (PD 0332991) …
advances in research, new therapies targeted to tumor biology are emerging to treat the
most common form of this disease. Cyclin-dependent kinase (CDK) 4/6 inhibitors are a new
class of therapeutic agents that have the potential to improve the outcomes of patients with
hormone receptor-positive (HR+) breast cancer. Three CDK 4/6 inhibitors have been
investigated for the treatment of HR+ breast cancer, including palbociclib (PD 0332991) …